Efficiency and Safety a Fixed Combination of Orphenadrine and Diclofenac for Postoperative Analgesia
Efficiency and Safety a Fixed Combination of Orphenadrine and Diclofenac for Postoperative Analgesia in Cardiac Surgery Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Lyubov S. Sorokina
- Phone Number: 89032157229
- Email: soroka300@gmail.ru
Study Locations
-
-
-
Moscow, Russian Federation
- Petrovsky Research National Centre of Surgery
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age from 18 years to 80 years inclusive
- surgical access - median sternotomy
- the first 2 hours after tracheal extubation
- clear consciousness and productive contact with the patient
- absence of erosive or ulcerative lesions of the mucous membrane of the esophagus, stomach and duodenum during preoperative esophago-gastro-duodenoscopy and clinical manifestations of gastrointestinal bleeding
- no signs of renal dysfunction (KDIGO 0)
- stable state of hemodynamics
Exclusion Criteria:
- a history of mental illness
- the presence of contraindications to the appointment of diclofenac and orphenadrine or individual intolerance to drugs of these groups
- renal and hepatic insufficiency
- perioperative brain lesions
- postoperative bleeding>1.4 ml/kg/hour
- severe cardiovascular (inotropic index>10) and/or respiratory (RaO2 /FiO2<200 mmHg) insufficiency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: the first group: a fixed combination of Orphenadrine and Diclofenac
dynamics of points 100 mm visual-analog scale,minute inspiratory lung volume
|
A decrease in the pain severity (VAS);opioid-sparing effect
Other Names:
|
|
Experimental: the second group: patient-controlled analgesia (РСА) with Morphine
dynamics of points 100 mm visual-analog scale,minute inspiratory lung volume
|
A decrease in the pain severity (VAS)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
visual-analog scale
Time Frame: hospitalisation period, an average of 24 hours
|
dynamics of points 100 mm visual-analog scale
|
hospitalisation period, an average of 24 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the minute inspiratory lung volume using a spirometer
Time Frame: hospitalisation period, an average of 24 hours
|
Comparison of minute inspiratory lung volume befor/after research using a spirometer
|
hospitalisation period, an average of 24 hours
|
|
opioid-sparing effect
Time Frame: hospitalisation period, an average of 24 hours
|
Comparison of the number of opioid analgesics
|
hospitalisation period, an average of 24 hours
|
|
adverse events
Time Frame: hospitalisation period, an average of 1 week
|
registration of adverse events
|
hospitalisation period, an average of 1 week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Lyubov S. Sorokina, anesthesiologist-resuscitator
- Study Director: Alexander A. Eremenko, prof, Head of the Intensive Care Unit
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Perceptual Disorders
- Agnosia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Analgesics, Opioid
- Narcotics
- Morphine
- Diclofenac
- Analgesics
- Analgesics, Non-Narcotic
Other Study ID Numbers
Other Study ID Numbers
- 00191200
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.